Chromosome 17 alterations identify goodrisk and poor-risk tumors independently of clinical factors in medulloblastoma

Neuro-Oncology

Volumn 13, Issue 4, 2011, Pages 376-383

  McCabe, Martin G ^a   Bäcklund, L Magnus ^b   Leong, Hui Sun ^c   Ichimura, Koichi ^d   Collins, V Peter ^d  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b KAROLINSKA INSTITUTE   (Sweden)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

^d UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

17 q gain; 17p loss; Cytogenetic; I(17q); Isochromosome; Lq gain; Medulloblastoma; Monosomy 6; Risk stratification; Survival

Indexed keywords

ANTINEOPLASTIC AGENT;

ADULT; ANAPLASTIC CARCINOMA; ARTICLE; CANCER RISK; CHILD; CHROMOSOME 17; CHROMOSOME 17Q; CHROMOSOME 1Q; CHROMOSOME ABERRATION; CHROMOSOME GAIN; CHROMOSOME LOSS; COPY NUMBER VARIATION; DISEASE SEVERITY; GENETIC RISK; GROUPS BY AGE; HUMAN; MAJOR CLINICAL STUDY; MEDULLOBLASTOMA; METASTASIS; PROGNOSIS; SURVIVAL; TREATMENT OUTCOME;

ADOLESCENT; ADULT; CEREBELLAR NEOPLASMS; CHILD; CHILD, PRESCHOOL; CHROMOSOME ABERRATIONS; CHROMOSOMES, HUMAN, PAIR 17; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; INFANT; INFANT, NEWBORN; MEDULLOBLASTOMA; PROGNOSIS; RISK FACTORS; SURVIVAL RATE; YOUNG ADULT;

EID: 79955770430     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/noq192     Document Type: Article

References (40)

1. Gajjar A, Chintagumpala M, Ashley D, et al. Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue In children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): long-term results from a prospective, multicentre trial. Lancet Oncol. 2006; 7(10):813-820. (Pubitemid 44464063)
2. Merchant TE, Kun LE, Krasin MJ, et al. Multi-institution prospective trial of reduced-dose craniospinal irradiation (23.4 Gy) followed by conformal posterior fossa (36 Gy) and primary site irradiation (55.8 Gy) and dose-intensive chemotherapy for average-risk medulloblastoma. Int J Radiat Oncol Biol Phys. 2008; 70(3):782-787. (Pubitemid 351199711)
3. Pomeroy SL, Tamayo P, Gaasenbeek M, et al. Prediction of central nervous system embryonal tumour outcome based on gene expression Nature. 2002; 415(6870):436-442. (Pubitemid 34100955)
4. Fernandez-Teijeiro A, Betensky RA, Sturla LM, Kim JY, Tamayo P, Pomeroy SL. Combining gene expression profiles and clinical parameters for risk stratification in medulloblastomas. J Clin Oncol. 2004; 22(6):994-998. (Pubitemid 41095030)
5. Eberhart CG, Kepner JL, Goldthwaite PT, et al. Histopathologic grading of medulloblastomas: a Pediatric Oncology Group study. Cancer. 2002; 94(2):552-560. (Pubitemid 34081387)
6. Giangaspero F, Wellek S, Masuoka J, Gessi M, Kleihues P, Ohgaki H Stratification of medulloblastoma on the basis of histopathological grading. Acta Neuropathol. 2006; 112(1):5-12. (Pubitemid 43942157)
7. Lamont JM, McManamy CS, Pearson AD, Clifford SC, Ellison DW. Combined histopathological and molecular cytogenetic stratification of medulloblastoma patients. Clin Cancer Res. 2004; 10(16):5482-5493. (Pubitemid 39100486)
8. Pfister S, Remke M, Benner A, et al. Outcome prediction in pediatric medulloblastoma based on DNA copy-number aberrations of chromosomes 6q and 17q and the MYC and MYCN loci. J Clin Oncol. 2009; 27(10):1627-1636.
9. Ellison DW, Onilude OE, Lindsey JC, et al. Beta-catenin status predicts a favorable outcome in childhood medulloblastoma: the United Kingdom Children's Cancer Study Group Brain Tumour Committee. J Clin Oncol. 2005; 23(31):7951-7957. (Pubitemid 46657395)
10. Fattet S, Haberler C, Legoix P, et al. Beta-catenin status in paediatric medulloblastomas: correlation of immunohistochemical expression with mutational status, genetic profiles, and clinical characteristics. J Pathol. 2009; 218(1):86-94.
11. De Bortoli M, Castellino RC, Lu XY, et al. Medulloblastoma outcome is adversely associated with overexpression of EEF1D, RPL30, and RPS20 on the long arm of chromosome 8. BMC Cancer. 2006; 6:223
12. de Haas T, Hasselt N, Troost D, et al. Molecular risk stratification of medulloblastoma patients based on immunohistochemical analysis of MYC, LDHB, and CCNB1 expression. Clin Cancer Res. 2008; 14(13):4154-4160.
13. Gilbertson R, Wickramasinghe C, Hernan R, et al. Clinical and molecular stratification of disease risk in medulloblastoma. Br J Cancer. 2001; 85(5):705-712. (Pubitemid 32929469)
14. Batra SK, McLendon RE, Koo JS, et al. Prognostic implications of chromosome 17p deletions in human medulloblastomas. J Neurooncol. 1995; 24(1)39-45.
15. Mendrzyk F, Radlwimmer B, Joos S, et al. Genomic and protein expression profiling identifies CDK6 as novel independent prognostic marker in medulloblastoma. J Clin Oncol. 2005; 23(34):8853-8862. (Pubitemid 46211532)
16. Pan E, Pellarin M, Holmes E, et al. Isochromosome 17q is a negative prognostic factor in poor-risk childhood medulloblastoma patients. Clin Cancer Res. 2005; 11(13):4733-4740. (Pubitemid 41557192)
17. Lo KC, Ma C, Bundy BN, Pomeroy SL, Eberhart CG, Cowell JK. Gain of 1q is a potential univariate negative prognostic marker for survival in medulloblastoma. Clin Cancer Res. 2007; 13(23):7022-7028. (Pubitemid 350276883)
18. Kool M, Koster J, Bunt J, et al. Integrated genomics identifies five medulloblastoma subtypes with distinct genetic profiles, pathway signatures and clinicopathological features. PLoS One. 2008; 3(8):e3088.
19. Thompson MC, Fuller C, Hogg TL, et al. Genomics identifies medulloblastoma subgroups that are enriched for specific genetic alterations. J Clin Oncol. 2006; 24(12):1924-1931 (Pubitemid 46638992)
20. McCabe MG, Ichimura K, Pearson DM, et al. Novel mechanisms of gene disruption at the medulloblastoma isodicentric 17p11 breakpoint. Genes Chromosomes Cancer. 2009; 48(2):121-131
21. DeChiara C, Borghese A, Fiorillo A, et al. Cytogenetic evaluation of isochromosome 17q in posterior fossa tumors of children and correlation with clinical outcome in medulloblastoma. Detection of a novel chromosomal abnormality. Childs Nerv Syst. 2002; 18(8)380-384. (Pubitemid 36013684)
22. Emadian SM, McDonald JD, Gerken SC, Fults D. Correlation of chromosome 17p loss with clinical outcome in medulloblastoma. Clin Cancer Res. 1996; 2(9):1559-1564. (Pubitemid 126447450)
23. Jung HL, Wang KC, Kim SK, et al. Loss of heterozygosity analysis of chromosome 17p13.1-13.3 and its correlation with clinical outcome in medulloblastomas. J Neurooncol. 2004; 67(1-2) 41-46. (Pubitemid 38418247)
24. q presence, proliferative and apoptotic indices, expression of c-erbB-2, bcl-2 and pp53 proteins on the prognosis of medulloblastoma. J Korean Med Sei. 2000; 15(4):452-456.
25. Zakrzewska M, Rieske P, Debiec-Rychter M, et al. Molecular abnormalities in pediatric embryonal brain tumors-analysis of loss of heterozygosity on chromosomes 1, 5, 9,10,11,16,17 and 22. Clin Neuropathol. 2004; 23(5):209-217. (Pubitemid 39222711)
26. R Development Core Team. R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing; 2008.
27. McCabe MG, Ichimura K, Liu L, et al. High-resolution array-based comparative genomic hybridization of medulloblastomas and supratentorial primitive neuroectodermal tumors. J Neuropathol Exp Neurol. 2006; 65(6):549-561 (Pubitemid 44288939)
28. Michiels EM, Weiss MM, Hoovers JM, et al. Genetic alterations in childhood medulloblastoma analyzed by comparative genomic hybridization. J Pediatr Hematol Oncol. 2002; 24(3):205-210. (Pubitemid 34297564)
29. Nicholson JC, Ross FM, Kohler JA, Ellison DW. Comparative genomic hybridization and histological variation in primitive neuroectodermal tumours. Br J Cancer. 1999; 80(9):1322-1331 (Pubitemid 29308599)
30. Reardon DA, Michalkiewicz E, Boyett JM, et al. Extensive genomic abnormalities in childhood medulloblastoma by comparative genomic hybridization. Cancer Res. 1997; 57(18):4042-4047. (Pubitemid 27427695)
31. Eberhart CG, Kratz JE, Schuster A, et al. Comparative genomic hybridization detects an increased number of chromosomal alterations In large cell/anaplastic medulloblastomas. Brain Pathol. 2002; 12(1):36-44. (Pubitemid 33131360)
32. von Hoff K, Hinkes B, Gerber NU, et al. Long-term outcome and clinical prognostic factors in children with medulloblastoma treated in the prospective randomised multicentre trial HIT'91. Eur J Cancer. 2009; 45(7):1209-1217.
33. Taylor RE, Bailey CC, Robinson K, et al. Results of a randomized study of preradiation chemotherapy versus radiotherapy alone for nonmetastatic medulloblastoma: The International Society of Paediatric Oncology/United Kingdom Children's Cancer Study Group PNET-3 Study. J Clin Oncol. 2003; 21(8):1581-1591 (Pubitemid 46594113)
34. Zeltzer PM, Boyett JM, Finlay JL, et al. Metastasis stage, adjuvant treatment, and residual tumor are prognostic factors for medulloblastoma in children: conclusions from the Children's Cancer Group 921 randomized phase III study. J Clin Oncol. 1999; 17(3):832-845. (Pubitemid 29109313)
35. p deletions in childhood primitive neuroectodermal tumors (medulloblastomas) of the central nervous system. Clin Cancer Res. 1997; 3(3):473-478. (Pubitemid 27158073)
36. p. Genomics. 1990; 8(2):279-285. (Pubitemid 20335619)
37. Kresse SH, Skarn M, Ohnstad HO, et al. DNA copy number changes in high-grade malignant peripheral nerve sheath tumors by array CGH Mol Cancer. 2008; 7:48.
38. Schleiermacher G, Michon J, Huon I, et al. Chromosomal CGH identifies patients with a higher risk of relapse in neuroblastoma without MYCN amplification. Br J Cancer. 2007; 97(2):238-246. (Pubitemid 47057465)
39. Alers JC, Rochat J, Krijtenburg PJ, et al. Identification of genetic markers for prostatic cancer progression. Lab Invest. 2000; 80(6):931-942 (Pubitemid 30421809)
40. Clifford SC, Lusher ME, Lindsey JC, et al. Wnt/Wingless pathway activation and chromosome 6 loss characterize a distinct molecular subgroup of medulloblastomas associated with a favorable prognosis. Cell Cycle. 2006; 5(22):2666-2670.